ES2142353T3 - Procedimiento para reducir los niveles de colesterol total y de colesterol asociado a lipoproteinas de baja densidad en sangre. - Google Patents

Procedimiento para reducir los niveles de colesterol total y de colesterol asociado a lipoproteinas de baja densidad en sangre.

Info

Publication number
ES2142353T3
ES2142353T3 ES93921585T ES93921585T ES2142353T3 ES 2142353 T3 ES2142353 T3 ES 2142353T3 ES 93921585 T ES93921585 T ES 93921585T ES 93921585 T ES93921585 T ES 93921585T ES 2142353 T3 ES2142353 T3 ES 2142353T3
Authority
ES
Spain
Prior art keywords
blood
cholesterol
reduce
low
procedure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93921585T
Other languages
English (en)
Spanish (es)
Inventor
Steven L Nissen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Iowa State University Research Foundation Inc ISURF
Original Assignee
Iowa State University Research Foundation Inc ISURF
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25484425&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2142353(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Iowa State University Research Foundation Inc ISURF filed Critical Iowa State University Research Foundation Inc ISURF
Application granted granted Critical
Publication of ES2142353T3 publication Critical patent/ES2142353T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Epoxy Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES93921585T 1992-09-16 1993-09-15 Procedimiento para reducir los niveles de colesterol total y de colesterol asociado a lipoproteinas de baja densidad en sangre. Expired - Lifetime ES2142353T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US94640492A 1992-09-16 1992-09-16

Publications (1)

Publication Number Publication Date
ES2142353T3 true ES2142353T3 (es) 2000-04-16

Family

ID=25484425

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93921585T Expired - Lifetime ES2142353T3 (es) 1992-09-16 1993-09-15 Procedimiento para reducir los niveles de colesterol total y de colesterol asociado a lipoproteinas de baja densidad en sangre.

Country Status (12)

Country Link
US (1) US5360613A (cg-RX-API-DMAC7.html)
EP (1) EP0660706B1 (cg-RX-API-DMAC7.html)
JP (1) JP3148243B2 (cg-RX-API-DMAC7.html)
AU (1) AU673002B2 (cg-RX-API-DMAC7.html)
BR (1) BR9307035A (cg-RX-API-DMAC7.html)
CA (1) CA2142314C (cg-RX-API-DMAC7.html)
DE (1) DE69327468T2 (cg-RX-API-DMAC7.html)
ES (1) ES2142353T3 (cg-RX-API-DMAC7.html)
FI (1) FI951218A7 (cg-RX-API-DMAC7.html)
NO (1) NO951000D0 (cg-RX-API-DMAC7.html)
NZ (1) NZ256300A (cg-RX-API-DMAC7.html)
WO (1) WO1994006417A1 (cg-RX-API-DMAC7.html)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5716926A (en) * 1996-07-26 1998-02-10 Paxton K. Beale Composition of pyruvate and protein and method for increasing protein concentration in a mammal
US5756469A (en) * 1996-07-26 1998-05-26 Beale; Paxton K. Composition of pyruvate and anti-cortisol compounds and method for increasing protein concentration in a mammal
US6103764A (en) * 1997-11-07 2000-08-15 Iowa State University Research Foundation, Inc. Method for increasing the aerobic capacity of muscle
US6031000A (en) * 1998-06-23 2000-02-29 Iowa State University Research Foundation, Inc. Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use
AU2620600A (en) * 1999-01-21 2000-08-07 Steroidogenesis Inhibitors International Composition of anti-hiv drugs and anti-cortisol compounds and method for decreasing the side effects of anti-hiv drugs in a human
CN100542525C (zh) 2001-05-18 2009-09-23 隆萨股份公司 制备3-羟基-3-甲基丁酸钠固体制剂的方法
US20040220266A1 (en) * 2002-09-09 2004-11-04 Wiley David B. Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives
US20040048925A1 (en) * 2002-09-09 2004-03-11 Wiley David B. Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives
US20040106678A1 (en) * 2002-09-17 2004-06-03 Dobbins Thomas A Compositions for the parenteral administration of calcium and magnesium
US6812249B2 (en) * 2003-03-04 2004-11-02 Sal Abraham Process for preparing a 3-hydroxy-3-methylbutyrate amino acid salt and method of use
EP1750527A1 (en) * 2004-03-11 2007-02-14 Wiley Organics, Inc. Compositions and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives
US20050215640A1 (en) 2004-03-26 2005-09-29 Baxter Jeffrey H HMB compositions and uses thereof
EP1973426A2 (en) * 2005-11-03 2008-10-01 Southwest Immunology Inc. Compositions for preventing and reducing delayed onset muscle soreness
EP1968564B1 (en) 2005-12-19 2015-09-16 Abbott Laboratories Use of beta-hydroxy-beta-methylbutyrate to modulate the imbalance in type 1 and type 2 cytokine production
US20080200422A1 (en) * 2007-01-09 2008-08-21 Cavener Douglas R Methods for reduction of adipose tissue mass
US9770424B2 (en) 2008-12-09 2017-09-26 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
US9539224B2 (en) 2008-12-09 2017-01-10 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
US9707241B2 (en) 2008-12-09 2017-07-18 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
US11173167B2 (en) 2008-12-09 2021-11-16 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
US9259430B2 (en) 2008-12-09 2016-02-16 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
US8815280B2 (en) * 2008-12-09 2014-08-26 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
US8538727B2 (en) * 2009-07-21 2013-09-17 George S. Cembrowski Method and apparatus for calibration and testing of scientific measurement equipment
US11042605B2 (en) 2009-07-21 2021-06-22 Ccqcc Corp. Method and apparatus for calibration and testing of scientific measurement equipment
SG182808A1 (en) 2010-01-29 2012-09-27 Abbott Lab Aseptically packaged nutritional liquids comprising hmb
WO2011094557A1 (en) 2010-01-29 2011-08-04 Abbott Laboratories Nutritional emulsions comprising calcium hmb
US9693577B2 (en) 2010-01-29 2017-07-04 Abbott Laboratories Method of preparing a nutritional powder comprising spray dried HMB
TWI526161B (zh) 2010-06-10 2016-03-21 亞培公司 包含鈣ｈｍｂ及可溶性蛋白質之實質上透明營養液
JP6158801B2 (ja) * 2011-07-15 2017-07-05 ニューサート サイエンシーズ， インコーポレイテッド 代謝経路を変調させるための組成物および方法
PH12014500329A1 (en) * 2011-08-15 2014-04-14 Abbott Laboaratories Process for manufacturing hmb and salts thereof
WO2013067485A1 (en) 2011-11-03 2013-05-10 University Of Florida Research Foundation, Inc. Nutritional supplement for weight management
WO2012140276A2 (en) * 2011-11-17 2012-10-18 Lonza Ltd Process for the preparation of 3-hydroxy-3-methylbutyric acid or its calcium salts
JP6258943B2 (ja) 2012-09-10 2018-01-10 メタボリック・テクノロジーズ，インコーポレーテッド Ｈｍｂおよびａｔｐの組成物ならびに使用方法
CA2944004C (en) 2014-03-27 2023-08-15 Roland W. Winterfield Beta-hydroxy beta-methylbutyrate for alleviating statin myopathy
DK3349745T3 (da) 2015-09-16 2024-03-18 Metabolic Tech Llc Sammensætninger og fremgangsmåder til anvendelse af beta-hydroxy-beta-methylbutyrat (hmb) til forbedret restitution efter blødvævstraume
US12208073B2 (en) 2015-09-16 2025-01-28 Metabolic Technologies, LLC Compositions and methods of use of beta-hydroxy-beta-methylbutyrate (HMB) for enhancing recovery from soft tissue trauma
TWI716495B (zh) * 2015-11-19 2021-01-21 日商協和發酵生化股份有限公司 3-羥基異戊酸之一價陽離子鹽之結晶及該結晶之製造方法
WO2017127675A1 (en) 2016-01-21 2017-07-27 Metabolic Technololgies, Inc. COMPOSITIONS AND METHODS OF USE OF β-HYDROXY-β-METHYLBUTYRATE (HMB) FOR MODULATING AUTOPHAGY AND LIPOPHAGY
CA3028608A1 (en) 2016-06-24 2017-12-28 Otsuka Pharmaceutical Factory, Inc. Crystal of amino acid salt of 3-hydroxyisovaleric acid and production method thereof
CA3041520A1 (en) 2016-10-21 2018-04-26 Metabolic Technologies, Inc. Compositions and methods of use of .beta.-hydroxy-.beta.-methylbutyrate (hmb) and probiotics

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3629449A (en) * 1968-04-22 1971-12-21 Majid Siddiqi Process of combatting hypercholesterolemia
US4760090A (en) * 1986-03-11 1988-07-26 Iowa State University Research Foundation, Inc. Method of feeding ketoisocaproate to cattle and sheep
US4764531A (en) * 1986-03-11 1988-08-16 Iowa State University Research Foundation, Inc. Method of feeding ketoisocaproate to laying chickens
US5087472A (en) * 1990-01-30 1992-02-11 Iowa State University Research Foundation, Inc. Feed compositions for domestics animals containing hydroxymethylbutyrate
US5028440A (en) * 1990-01-30 1991-07-02 Iowa State University Research Foundation, Inc. Method of raising meat producing animals to increase lean tissue development
US4992470A (en) * 1990-02-08 1991-02-12 Iowa State University Research Foundation, Inc. Method of enhancing immune response of mammals

Also Published As

Publication number Publication date
DE69327468D1 (de) 2000-02-03
US5360613A (en) 1994-11-01
NO951000L (no) 1995-03-15
NO951000D0 (no) 1995-03-15
CA2142314C (en) 1999-06-01
FI951218A0 (fi) 1995-03-15
DE69327468T2 (de) 2000-05-11
AU4922593A (en) 1994-04-12
NZ256300A (en) 1997-06-24
FI951218L (fi) 1995-03-15
AU673002B2 (en) 1996-10-24
EP0660706B1 (en) 1999-12-29
WO1994006417A1 (en) 1994-03-31
EP0660706A1 (en) 1995-07-05
CA2142314A1 (en) 1994-03-31
EP0660706A4 (cg-RX-API-DMAC7.html) 1995-07-26
JPH08501777A (ja) 1996-02-27
BR9307035A (pt) 1999-06-29
FI951218A7 (fi) 1995-03-15
JP3148243B2 (ja) 2001-03-19

Similar Documents

Publication Publication Date Title
ES2142353T3 (es) Procedimiento para reducir los niveles de colesterol total y de colesterol asociado a lipoproteinas de baja densidad en sangre.
Lebwohl et al. Effects of topical preparations on the erythemogenicity of UVB: implications for psoriasis phototherapy
ES2080042T3 (es) Composiciones para modular el efecto de tnf e il-1.
ES2162615T3 (es) Metodo para tratar o prevenir diabetes de tipo 1 mediante la administracion oral de insulina.
ES2164097T3 (es) Uso de anestesicos topicos para la fabricacion de un medicamento para el tratamiento del asma bronquial.
DK0998288T4 (da) Sammensætninger indeholdende kapasaicin eller kapsaicinanaloge og et lokalbedövelsesmiddel
DK0542864T3 (da) Anvendelse af phospholipider til fremstilling af et topisk lægemiddel til modifikation af serumcholesterolniveauer
ES2186714T3 (es) Uso de sustipo simple alpha 8 en la preparacion de medicamentos para el tratamiento de infecciones virales del higado.
ES2074565T3 (es) Empleo de melatonina para tratar el sindrome pre-menstrual.
ES2130152T3 (es) Medicamentos para tratar dolencias inflamatorias o para analgesia que contienen un nsaid y ranitidina/citrato de bismuto.
ES2184145T3 (es) Compuestos de acido sulfonico o sulfonilamino-n-(heteroaralquil)-azaheterociclilamida.
SE9003395D0 (sv) Anvaendning av inositoltrifosfat foer framstaellning av laekemedel
DK258884A (da) Peptider og farmaceutisk praeparat indeholdende et saadant peptid
DK0484112T3 (da) Anvendelse af lithium ved behandlingen eller profylakse af Molluscum contagiosum
MX9400040A (es) Composiciones para tratar trastornos respiratorios.
ES2038716T3 (es) Metodos y composiciones para el tratamiento de la psoriasis.
ES2052776T3 (es) Derivados o-alcanoilo del acido 3-amino-2-hidroxipropansulfonico con actividad anticonvulsiva y composiciones farmaceuticas que los contienen para el tratamiento terapeutico de epilepsia.
ES2165855T3 (es) Agente de normalizacion de la coagulacion sanguinea que contiene tcf-ii como ingrediente activo.
KR950700737A (ko) 기도 염증 및 기도 과잉반응의 치료약품(Medicament for the treatment of airways inflammation and airways hyperresponsiveness)
DE3602965A1 (de) Geraet zur bestrahlung des herpes simplex
ES2053925T3 (es) Una composicion para el tratamiento de pacientes con sindrome de inmunodeficiencia adquirida.
MX9302303A (es) Derivados monocuaternarioos de 2,16-bispiperidinilandrostano.
MX9304878A (es) Uso de un azaspirano substituido en la fabricacion de un medicamento para utilizarse en el tratamiento de psoriasis.
ES2153828T3 (es) Composiciones que contienen insulina y amilina para el tratamiento de mamiferos deficientes en insulina.
Whitley et al. Identification and management of psychosocial and environmental problems of children with cancer

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 660706

Country of ref document: ES